Cytodyn Inc (CYDY)

[Monroe1]

good post.

Aaron Kesselheim, professor of medicine at Harvard Medical School, told Focus: “Historically, FDA guidance seemed to indicate a preference for two adequate and well-controlled trials since any single trial may be subject to unanticipated or undetected systematic biases. Of course, in some cases, the clinical need is high enough or the drug’s efficacy is powerful enough that a single trial should be sufficient at least for initial FDA approval.

Sure sounds like Leronlimab fits the bill!